JP2020091296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020091296A5 JP2020091296A5 JP2020018129A JP2020018129A JP2020091296A5 JP 2020091296 A5 JP2020091296 A5 JP 2020091296A5 JP 2020018129 A JP2020018129 A JP 2020018129A JP 2020018129 A JP2020018129 A JP 2020018129A JP 2020091296 A5 JP2020091296 A5 JP 2020091296A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory agent
- combination
- pkal inhibitor
- pkal
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 20
- 230000002401 inhibitory effect Effects 0.000 claims 20
- 239000002260 anti-inflammatory agent Substances 0.000 claims 19
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 17
- 238000004166 bioassay Methods 0.000 claims 6
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 5
- 102100011311 KNG1 Human genes 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 2
- 102000003827 Plasma kallikrein Human genes 0.000 claims 2
- 108090000113 Plasma kallikrein Proteins 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
Claims (16)
- 対象における自己免疫疾患の治療における使用のための血漿カリクレイン（ｐＫａｌ）阻害剤、抗炎症剤またはそれらの組み合わせであって、
前記対象は、対照試料と比較して上昇している切断型高分子量キニノーゲン（ＨＭＷＫ）のレベルを有する、
血漿カリクレイン（ｐＫａｌ）阻害剤、抗炎症剤またはそれらの組み合わせ。 - 前記自己免疫疾患が、関節リウマチ（ＲＡ）、クローン病（ＣＤ）もしくは潰瘍性大腸炎（ＵＣ）である、請求項１に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記対象は、前記ｐＫａｌ阻害剤を投与される、請求項１または２に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記ｐＫａｌ阻害剤は、Ｋｕｎｉｔｚドメインポリペプチドであるか、またはｐＫａｌに結合する抗体である、請求項１〜３のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記ｐＫａｌ阻害剤は、ＤＸ−２９３０、ＤＸ−８８またはＥＰＩＫＡＬ−２である、請求項１〜４のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記対象は、前記抗炎症剤を投与される、請求項１〜５のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記抗炎症剤は、ステロイドまたは非ステロイド性抗炎症薬（ＮＳＡＩＤ）である、請求項１〜６のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 切断型ＨＭＷＫのレベルが、切断型ＨＭＷＫに特異的な結合剤を含むアッセイで測定される、請求項１〜７のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記アッセイが、前記対象の１つ以上の生物学的試料を準備することを伴う、請求項８に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記１つ以上の生物学的試料が血清試料もしくは血漿試料である、請求項９に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記生物学的試料のうちの少なくとも１つが、その採取後に前記試料へと添加される一つもしくはそれ以上のプロテアーゼ阻害剤を含む、請求項１０に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記対象がヒト対象である、請求項１〜１１のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記対照試料は、健康な対象からの試料である、請求項１〜１２のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記結合剤は、切断型ＨＭＷＫに結合する抗体である、請求項８〜１３のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記アッセイが、酵素結合免疫吸着測定法（ＥＬＩＳＡ）もしくはイムノブロットアッセイである、請求項８〜１４のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
- 前記アッセイがウェスタンブロットアッセイである、請求項８〜１５のいずれか１項に記載のｐＫａｌ阻害剤、抗炎症剤またはそれらの組み合わせ。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022161469A JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893542P | 2013-10-21 | 2013-10-21 | |
| US61/893,542 | 2013-10-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549205A Division JP6657098B2 (ja) | 2013-10-21 | 2014-10-17 | 自己免疫疾患の診断と治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161469A Division JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020091296A JP2020091296A (ja) | 2020-06-11 |
| JP2020091296A5 true JP2020091296A5 (ja) | 2020-11-12 |
| JP7157089B2 JP7157089B2 (ja) | 2022-10-19 |
Family
ID=52993412
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549205A Active JP6657098B2 (ja) | 2013-10-21 | 2014-10-17 | 自己免疫疾患の診断と治療 |
| JP2020018129A Active JP7157089B2 (ja) | 2013-10-21 | 2020-02-05 | 自己免疫疾患の診断と治療 |
| JP2022161469A Pending JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549205A Active JP6657098B2 (ja) | 2013-10-21 | 2014-10-17 | 自己免疫疾患の診断と治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161469A Pending JP2022191343A (ja) | 2013-10-21 | 2022-10-06 | 自己免疫疾患の診断と治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10101344B2 (ja) |
| EP (2) | EP3913364A1 (ja) |
| JP (3) | JP6657098B2 (ja) |
| KR (3) | KR102295623B1 (ja) |
| CN (2) | CN105874332B (ja) |
| AU (3) | AU2014340449B2 (ja) |
| BR (1) | BR112016008975B1 (ja) |
| CA (1) | CA2927695C (ja) |
| DK (1) | DK3060908T3 (ja) |
| ES (1) | ES2873204T3 (ja) |
| IL (4) | IL293948A (ja) |
| PL (1) | PL3060908T3 (ja) |
| PT (1) | PT3060908T (ja) |
| WO (1) | WO2015061182A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| PL3060582T3 (pl) | 2013-10-21 | 2021-05-04 | Dyax Corp. | Testy do oznaczania biomarkerów układu kalikreiny osoczowej |
| IL293948A (en) * | 2013-10-21 | 2022-08-01 | Dyax Corp | Diagnosis and treatment of autoimmune diseases |
| ES2857552T3 (es) * | 2015-10-19 | 2021-09-29 | Takeda Pharmaceuticals Co | Inmunoensayo para detectar cininógenos de alto peso molecular escindido |
| KR102513485B1 (ko) * | 2016-09-16 | 2023-03-23 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| KR200490846Y1 (ko) | 2019-04-09 | 2020-01-13 | 이대호 | 각도조절 브라켓 |
| KR20230050770A (ko) | 2021-10-08 | 2023-04-17 | 김경민 | 발로 열 수 있는 반려동물 울타리 |
| WO2024003617A2 (en) * | 2022-06-30 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPS63185398A (ja) | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5472945A (en) | 1991-08-13 | 1995-12-05 | Temple University- Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5795865A (en) | 1994-01-11 | 1998-08-18 | Dyax Corp. | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| EP0852004B1 (en) | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| JP4106888B2 (ja) | 2001-09-19 | 2008-06-25 | カシオ計算機株式会社 | 液晶表示装置および携帯端末装置 |
| US8148171B2 (en) | 2001-10-09 | 2012-04-03 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| US7435542B2 (en) | 2002-06-24 | 2008-10-14 | Cornell Research Foundation, Inc. | Exhaustive selection of RNA aptamers against complex targets |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| AU2003280241A1 (en) | 2002-11-01 | 2004-05-25 | Mcmaster University | Multicomponent protein microarrays |
| WO2005024042A2 (en) | 2003-09-04 | 2005-03-17 | The Regents Of The University Of California | Aptamers and methods for their in vitro selection and uses thereof |
| WO2005049826A1 (ja) | 2003-11-22 | 2005-06-02 | Ultizyme International Ltd. | アプタマーを用いた標的分子の検出方法 |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| EP1981519B1 (en) * | 2005-12-29 | 2017-12-27 | Dyax Corp. | Protease inhibition |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| EP2089712A4 (en) * | 2006-11-22 | 2010-09-22 | Life Technologies Corp | BIOMARKERS OF AUTOIMMUNE DISEASES |
| US20080255766A1 (en) | 2007-02-16 | 2008-10-16 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of sickle cell |
| CA2696208A1 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| CA2703264A1 (en) | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| US20110160434A1 (en) * | 2008-07-07 | 2011-06-30 | Nippon Zoki Pharmaceutical Co., Ltd. | Fibromyalgia test method |
| WO2010062663A1 (en) * | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20110318359A1 (en) | 2008-12-02 | 2011-12-29 | Feener Edward P | Method for reducing blood pressure using inhibitors of plasma kallikrein |
| AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| KR101077275B1 (ko) * | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JP5299179B2 (ja) * | 2009-09-02 | 2013-09-25 | 株式会社リコー | 画像形成装置 |
| EP2512466A4 (en) * | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| US9206123B2 (en) * | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
| WO2012009447A2 (en) * | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| BR112013017080A8 (pt) * | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
| US9187749B2 (en) * | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| IL293948A (en) | 2013-10-21 | 2022-08-01 | Dyax Corp | Diagnosis and treatment of autoimmune diseases |
| PL3060582T3 (pl) | 2013-10-21 | 2021-05-04 | Dyax Corp. | Testy do oznaczania biomarkerów układu kalikreiny osoczowej |
| ES2857552T3 (es) | 2015-10-19 | 2021-09-29 | Takeda Pharmaceuticals Co | Inmunoensayo para detectar cininógenos de alto peso molecular escindido |
| US20230072523A1 (en) * | 2020-01-28 | 2023-03-09 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 IL IL293948A patent/IL293948A/en unknown
- 2014-10-17 EP EP21158440.4A patent/EP3913364A1/en active Pending
- 2014-10-17 CN CN201480069823.8A patent/CN105874332B/zh active Active
- 2014-10-17 EP EP14855002.3A patent/EP3060908B1/en active Active
- 2014-10-17 DK DK14855002.3T patent/DK3060908T3/da active
- 2014-10-17 KR KR1020167013312A patent/KR102295623B1/ko active IP Right Grant
- 2014-10-17 PT PT148550023T patent/PT3060908T/pt unknown
- 2014-10-17 WO PCT/US2014/061242 patent/WO2015061182A1/en active Application Filing
- 2014-10-17 KR KR1020237000230A patent/KR102665705B1/ko active IP Right Grant
- 2014-10-17 ES ES14855002T patent/ES2873204T3/es active Active
- 2014-10-17 US US15/030,790 patent/US10101344B2/en active Active
- 2014-10-17 KR KR1020217026950A patent/KR102485948B1/ko active IP Right Grant
- 2014-10-17 IL IL284969A patent/IL284969B/en unknown
- 2014-10-17 AU AU2014340449A patent/AU2014340449B2/en active Active
- 2014-10-17 CA CA2927695A patent/CA2927695C/en active Active
- 2014-10-17 CN CN201910994046.2A patent/CN110658337B/zh active Active
- 2014-10-17 JP JP2016549205A patent/JP6657098B2/ja active Active
- 2014-10-17 PL PL14855002T patent/PL3060908T3/pl unknown
- 2014-10-17 BR BR112016008975-8A patent/BR112016008975B1/pt active IP Right Grant
-
2016
- 2016-04-19 IL IL245206A patent/IL245206B/en active IP Right Grant
-
2018
- 2018-09-14 US US16/131,781 patent/US10648990B2/en active Active
-
2020
- 2020-01-21 AU AU2020200423A patent/AU2020200423B2/en active Active
- 2020-02-05 JP JP2020018129A patent/JP7157089B2/ja active Active
- 2020-04-15 US US16/849,492 patent/US20200371120A1/en active Pending
- 2020-06-14 IL IL275368A patent/IL275368B/en unknown
-
2022
- 2022-06-29 AU AU2022204649A patent/AU2022204649A1/en active Pending
- 2022-10-06 JP JP2022161469A patent/JP2022191343A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020091296A5 (ja) | ||
| Wang et al. | Neutrophil extracellular trap-microparticle complexes enhance thrombin generation via the intrinsic pathway of coagulation in mice | |
| Ali et al. | Lectin pathway mediates complement activation by SARS-CoV-2 proteins | |
| Rasmussen et al. | Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation | |
| Corsiero et al. | NETosis as source of autoantigens in rheumatoid arthritis | |
| Juvonen et al. | Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm | |
| Chaaban et al. | Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury | |
| Koenig-Oberhuber et al. | New antiplatelet drugs and new oral anticoagulants | |
| Carbone et al. | Pathophysiological role of neutrophils in acute myocardial infarction | |
| Kwasny-Krochin et al. | Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis | |
| Stephan et al. | Activation of factor VII-activating protease in human inflammation: a sensor for cell death | |
| Chang et al. | The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis | |
| Misra et al. | Mechanisms of thrombosis in ANCA-associated vasculitis | |
| Apetrii et al. | A brand-new cardiorenal syndrome in the COVID-19 setting | |
| Tomerak et al. | Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: a systematic review | |
| Furio et al. | CX3CR1/CX3CL1 Axis Mediates Platelet–Leukocyte Adhesion to Arterial Endothelium in Younger Patients with a History of Idiopathic Deep Vein Thrombosis | |
| JP2017500584A5 (ja) | ||
| Hisada et al. | Circulating tissue factor‐positive extracellular vesicles and their association with thrombosis in different diseases | |
| Boon et al. | Citrullination as a novel posttranslational modification of matrix metalloproteinases | |
| Wick et al. | Anti‐apolipoprotein A‐1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis | |
| Dumestre-Perard et al. | Complement C4 monitoring in the follow-up of chronic hepatitis C treatment | |
| Rahman et al. | Mucosal serpin A1 and A3 levels in HIV highly exposed sero‐negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders | |
| Spaeny-Dekking et al. | Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors | |
| El-Ghafar et al. | Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways | |
| Kimura et al. | Identification of citrullinated cellular fibronectin in synovial fluid from patients with rheumatoid arthritis |